The company is currently listed on Canada’s NEO exchange and has a market cap of $190 million. MindMed’s announcement comes just days after U.K.-based Compass Pathways, which has patented a synthetic form of psilocybin for use in treatment-resistant depression, went public on the Nasdaq. Compass’ IPO is perhaps a bellwether signaling that some Wall Street […]
Psychedelic Drug Company MindMed Applies For Nasdaq Up-Listing Read More »
While trying to understand what makes the psychedelic drug LSD work, Dr. Mattias Liechti, head of the Liechti Laboratory at the University of Basel Hospital, stumbled onto something unexpected. During his research, he found a substance that seemed to abort the hallucinogenic effects of LSD within 20 to 30 minutes. MindMed, a pharmaceutical company focused
This Company is Working on A Drug that Will Make LSD Less Trippy Read More »
While many people will look back on the pandemic as a dark time, it has also spurred some positive developments—most notably in the field of drug development, where miraculous breakthroughs like mRNA vaccines are transforming immunology. Now, a handful of companies believe the pandemic could lead to a profound change in how we address mental
Can LSD cure our pandemic anxiety? NeuroMind BioPharma is spending big to find out Read More »
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (“MindMed” or the “Company”) is pleased to announce that it has appointed Dr. Sarah Y. Vinson as a director of the Company and a member of its audit committee, effective immediately. Dr. Vinson is a Triple Board-Certified physician who specializes in adult, child & adolescent,
NeuroMind BioPharma Announces Appointment of Dr. Sarah Y. Vinson as Additional Director Read More »
MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announces receipt of Type C Meeting Responses from FDA leading to the finalization of the Company’s clinical development approach for Project Lucy by selecting Generalized Anxiety Disorder
NeuroMind BioPharma Announces the Approval of Mescaline Study
NeuroMind BioPharma Announces the Approval of Mescaline Study Read More »
